[go: up one dir, main page]

WO2024254190A3 - Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders - Google Patents

Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders Download PDF

Info

Publication number
WO2024254190A3
WO2024254190A3 PCT/US2024/032615 US2024032615W WO2024254190A3 WO 2024254190 A3 WO2024254190 A3 WO 2024254190A3 US 2024032615 W US2024032615 W US 2024032615W WO 2024254190 A3 WO2024254190 A3 WO 2024254190A3
Authority
WO
WIPO (PCT)
Prior art keywords
psychoactive
disorders
medicines
neurological conditions
treating psychiatric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/032615
Other languages
French (fr)
Other versions
WO2024254190A2 (en
Inventor
Blake MANDELL
Martin Stogniew
Jennifer Louise SCHMIDT
Markus SEELIG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transcend Therapeutics Inc
Original Assignee
Transcend Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transcend Therapeutics Inc filed Critical Transcend Therapeutics Inc
Priority to US18/784,243 priority Critical patent/US12343326B2/en
Priority to US18/790,708 priority patent/US12295937B2/en
Publication of WO2024254190A2 publication Critical patent/WO2024254190A2/en
Publication of WO2024254190A3 publication Critical patent/WO2024254190A3/en
Priority to US19/203,021 priority patent/US20250332139A1/en
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to psychoactive medicines including methylone, 2C-B, MBDB, their respective salts, metabolites, isomers, enantiomers, solvates, isotopologues and isotopomers, polymorphs, prodrugs and analogs (2C-series and cathinones); their preparation, formulations, intermediates, routes of administration, dosing and schedule for medical uses for psychiatric and neurological conditions and disorders.
PCT/US2024/032615 2021-08-06 2024-06-05 Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders Pending WO2024254190A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US18/784,243 US12343326B2 (en) 2021-08-06 2024-07-25 Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
US18/790,708 US12295937B2 (en) 2021-08-06 2024-07-31 Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
US19/203,021 US20250332139A1 (en) 2021-08-06 2025-05-08 Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US202363471412P 2023-06-06 2023-06-06
US63/471,412 2023-06-06
US202363602904P 2023-11-27 2023-11-27
US63/602,904 2023-11-27
US202363605729P 2023-12-04 2023-12-04
US63/605,729 2023-12-04
US202363607702P 2023-12-08 2023-12-08
US63/607,702 2023-12-08
US202463553788P 2024-02-15 2024-02-15
US63/553,788 2024-02-15
US202463649653P 2024-05-20 2024-05-20
US63/649,653 2024-05-20

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US18/784,243 Continuation US12343326B2 (en) 2021-08-06 2024-07-25 Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
US18/790,708 Continuation US12295937B2 (en) 2021-08-06 2024-07-31 Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
US19/203,021 Continuation US20250332139A1 (en) 2021-08-06 2025-05-08 Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders

Publications (2)

Publication Number Publication Date
WO2024254190A2 WO2024254190A2 (en) 2024-12-12
WO2024254190A3 true WO2024254190A3 (en) 2025-04-17

Family

ID=93794663

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/032615 Pending WO2024254190A2 (en) 2021-08-06 2024-06-05 Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders

Country Status (2)

Country Link
TW (1) TW202513053A (en)
WO (1) WO2024254190A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140142140A1 (en) * 2011-07-08 2014-05-22 Gosforth Centre (Holdings) Pty Ltd Pharmaceutical composition for neurological disorders
US20230054211A1 (en) * 2021-08-06 2023-02-23 Transcend Therapeutics, Inc. Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
US20230124101A1 (en) * 2020-11-18 2023-04-20 Bexson Biomedical, Inc. Complexing agent salt formulations of pharmaceutical compounds
WO2023081403A1 (en) * 2021-11-05 2023-05-11 Terran Biosciences Inc. Isotopologes, salts, crystalline forms, stereoisomers, of methylone and ethylone and methods of use thereof
US20240285576A1 (en) * 2023-02-28 2024-08-29 Mind Medicine, Inc. R-mdma for treatment of pain

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140142140A1 (en) * 2011-07-08 2014-05-22 Gosforth Centre (Holdings) Pty Ltd Pharmaceutical composition for neurological disorders
US20230124101A1 (en) * 2020-11-18 2023-04-20 Bexson Biomedical, Inc. Complexing agent salt formulations of pharmaceutical compounds
US20230054211A1 (en) * 2021-08-06 2023-02-23 Transcend Therapeutics, Inc. Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
WO2023081403A1 (en) * 2021-11-05 2023-05-11 Terran Biosciences Inc. Isotopologes, salts, crystalline forms, stereoisomers, of methylone and ethylone and methods of use thereof
US20240285576A1 (en) * 2023-02-28 2024-08-29 Mind Medicine, Inc. R-mdma for treatment of pain

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LI ZHENLONG, PENG HSIEN-YU, LEE CHAU-SHOUN, LIN TZER-BIN, HSIEH MING-CHUN, LAI CHENG-YUAN, WU HAN-FANG, CHEN LIH-CHYANG, CHEN MEI-: "Methylone produces antidepressant-relevant actions and prosocial effects", NEUROPHARMACOLOGY, vol. 242, 1 January 2024 (2024-01-01), AMSTERDAM, NL, pages 1 - 12, XP093306492, ISSN: 0028-3908, DOI: 10.1016/j.neuropharm.2023.109787 *

Also Published As

Publication number Publication date
TW202513053A (en) 2025-04-01
WO2024254190A2 (en) 2024-12-12

Similar Documents

Publication Publication Date Title
MX2024001654A (en) Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders.
CA2004747C (en) Substituted phenylpyrimidines useful in the treatment of cns disorders
BR112023001195A2 (en) COMPOUND OR RACEMATE, STEREOISOMER, TAUTOMER, ISOTOPICALLY LABELED COMPOUND, SOLVATE, POLYMORPH, PHARMACEUTICALLY ACCEPTABLE SALT OR PRODRUG COMPOUND THEREOF, COMPOUND, METHOD OF PREPARATION FOR COMPOUND OR RACEMATE, STEREOISOMER, TAUTOMER, ISOTOPICALLY LABELED COMPOUND, POLYFOLD, SALTED, SALTED ACCEPTABLE PHARMACEUTICALLY OR PRODRUG COMPOUND, PHARMACEUTICAL COMPOSITION, METHOD FOR TREAT A DISEASE ASSOCIATED WITH ALTERNATIVE COMPLEMENT PATHWAY ACTIVATION, AND, USE OF THE COMPOUND
ES2611657T3 (en) Factor Xa pyrazole-carboxamide inhibitors
HRP20220295T1 (en) 2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin
GT199900068A (en) SOLID COMPOSITIONS CONTAINING GABAPENTINE AND PROCESS FOR PREPARATION.
NZ515894A (en) Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
UY27092A1 (en) DERIVATIVES OF THE NEW QUINUCLIDINE CARBAMATE AND THE MEDICINAL COMPOSITIONS CONTAINING THEM
CO6290666A2 (en) NMDA RECEIVER ANTAGONISTS FOR NEUROPROTECTION
PE20000556A1 (en) STABILIZED PHARMACEUTICAL PREPARATIONS OF GABAPENTIN AND PROCESS FOR PREPARING IT
HUP0402649A2 (en) 6-fluorobicyclo[3.1.0]hexane derivatives
NO20024042D0 (en) Aryl-fused azapolycyclic compounds
AR062387A2 (en) THE USE OF A COMPOUND DERIVED FROM IMIDAZO [1,2-A] PIRIDINA, AND A MEDICINAL PRODUCT CONTAINING IT
ECSP034602A (en) SUBSTITUTED DERIVATIVES 2-PHENYLAMINOIMIDAZOLINE PHENYL KETONE AS IP ANTAGONISTS
WO2005002582A3 (en) Trp-p8 active compounds and therapeutic treatment methods
PH12020552111A1 (en) Benzenesulfonamide compounds and their use as therapeutic agents
MX2024003738A (en) Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds.
MX2024012095A (en) Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
ES8505914A1 (en) Catechol derivatives, their production and intermediates therefor, and pharmaceutical compositions containing them.
PH12021550146A1 (en) Condensed lactam derivative
WO2024254190A3 (en) Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
WO2019182904A1 (en) Phosphonamidate butyrophilin ligands
WO2020145831A8 (en) (2,5-dioxopyrrolidin-1-yl)(phenyl)-acetamide derivatives and their use in the treatment of neurological diseases
PH12021551447A1 (en) Analogues of pentamidine and uses therefor
BR112023001060A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, COMBINATION, PROCESS FOR MANUFACTURING A PHARMACEUTICAL COMPOSITION, AND, METHOD OF TREATMENT AND/OR PREVENTION OF A DISORDER

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: AU2024284688

Country of ref document: AU

Ref document number: 827546

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 827546

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2024284688

Country of ref document: AU

Date of ref document: 20240605

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112025026802

Country of ref document: BR